Abstract
Attempts to translate senolytics from preclinical models to humans are gaining momentum. Early clinical trials have provided positive biological signals, but we lack clear evidence for the efficacy of senolytics in humans. Based on what we have learned in these initial trials, it may be time to aim for a more personalized approach in designing future senolytic trials, and potentially also in the eventual clinical use of these compounds.